A study testing whether a study medicine from Novo Nordisk, cagrisema, can help with weight.

Who can join

Adults 18 to 65, have obesity, BMI 30+.

What you take

cagrisema, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 2.1 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet.

Primary condition: Obesity.

Who can join, in detail

Key inclusion criteria

• Male or female (sex assigned at birth).
• Age 18-65 years (both inclusive) at the time of signing the informed consent.
• Body Mass Index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m^2) at screening (Visit 1). Excess body weight should be due to excess adipose tissue, as judged by the investigator.

Key exclusion criteria

• Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.
• History of diabetes mellitus of any type, other than gestational diabetes mellitus.
• Claustrophobia or severe discomfort of being confined in small rooms.
• Contraindication for magnetic resonance imaging (MRI) scanning as per local guidance, including physical limitations that prevent the MRI scan.
• Unusual meal habits (including, but not limited to, eating disorders) and special diet requirements or unwillingness to eat the food provided in the study.

Where this study is enrolling

This trial has 2 US sites across 2 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2025-09-26. Expected completion: 2027-10-12. Last updated on ClinicalTrials.gov: 2025-10-08.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact